Please ensure Javascript is enabled for purposes of website accessibility

Zogenix's Positive Clinical Trial Wasn't Positive Enough

By Brian Orelli, PhD - Feb 7, 2020 at 2:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Rival GW Pharmaceuticals came out the big winner, as its competing seizure drug looks more effective.

Zogenix (ZGNX) reported what it called "positive" results from a late-stage clinical trial testing its drug candidate, Fintepla, in patients with a variety of childhood-onset epilepsy called Lennox-Gastaut syndrome. And technically, the company was right: Fintepla reduced the median number of monthly drop seizures by 26.5%, compared to a median reduction of 7.8% in patients taking a placebo.

But shares of Zogenix were down by 37% at 2:25 p.m. Friday because, while Fintepla did beat the placebo, that 26.5% reduction in seizures was fairly small. The highest dose of GW Pharmaceuticals' (GWPH) Epidiolex, a cannabidiol derived from cannabis, produced reductions of 42% and 44% in the two clinical trials that led the Food and Drug Administration to approve it for treating patients with Lennox-Gastaut syndrome. The placebo effects in the Epidiolex studies were higher, with reductions of 17% and 22%, respectively, but even factoring that in, it appears that Epidiolex (25% and 22% placebo-adjusted) works better than Fintepla (18.7% placebo-adjusted) in Lennox-Gastaut syndrome.

Shares of GW Pharmaceuticals were up almost 7% on news of its rival's positive-but-not-so-much results.

Doctor listening to a child's heart with a stethoscope

Image source: Getty Images.

The active ingredient in Fintepla is fenfluramine, half of the notorious weight-loss combo drug fen-phen, which was discovered to cause heart valve damage and was pulled from the market in 1997.

Zogenix has also tested Fintepla in Dravet syndrome, another form of childhood epilepsy, with better results: the highest dose studied reduced mean monthly convulsive seizures by more than 60% in two different clinical trials. The company has already submitted the data to the FDA, which is expected to make an approval decision by March 25.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zogenix, Inc. Stock Quote
Zogenix, Inc.
ZGNX
GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
GWPH

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.